Waldenstrom Macroglobulinemia: Tailoring Therapy for the Individual.
Waldenstrom Macroglobulinemia: Tailoring Therapy for the Individual.
复制标题
DOI：
10.1200/jco.22.00495
复制
发表时间：
2022-06
期刊：
影响因子：
--
通讯作者：
M. Gertz
中科院分区：
文献类型：
--
作者：
M. Gertz
随着多个新的有效的治疗巨球蛋白血症的治疗方案的引入，目前需要一个结构化的方法来管理这种罕见的淋巴瘤。对过去20年的II期和III期治疗试验进行了回顾，本手稿总结了高质量的试验。由于缺乏比较不同类别治疗的大型前瞻性试验，因此无法提出适用于所有患者的统一建议，并且必须根据患者的偏好，合并症和治疗毒性范围进行个性化治疗。新诊断和既往治疗的巨球蛋白血症患者的治疗选择是基于文献中现有的最佳证据。
With the introduction of multiple new effective therapeutic options for the treatment of macroglobulinemia, a structured approach to management of this rare lymphoma is currently needed. A review of phase II and III treatment trials over the past 20 years was performed, and high-quality trials are summarized in this manuscript. Because of the lack of large prospective trials comparing different classes of therapy, a uniform recommendation applicable to all patients cannot be made, and the approach must be individualized incorporating patient preferences, comorbidities, and the range of therapeutic toxicities. Therapeutic options for patients with newly diagnosed and previously treated macroglobulinemia are presented on the basis of the best available evidence in the literature.